SCHEMBL8966129

SCHEMBL8966129

CCC1Cc2ccccc2C(=O)N1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.62
BRD4 O60885 1/20 0.49
CREBBP Q92793 1/20 0.49
NPSR1 Q6W5P4 1/20 0.45
ACHE P22303 5/20 0.44
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
METAP1 P53582 2/20 0.41
PARP1 P09874 2/20 0.41
PDPK1 O15530 1/20 0.41
PARP10 Q53GL7 1/20 0.41
PARP11 Q9NR21 1/20 0.41
TDP2 O95551 1/20 0.41
CASP3 P42574 1/20 0.41
CASP7 P55210 1/20 0.41
CASP9 P55211 1/20 0.41
CASP6 P55212 1/20 0.41
CASP8 Q14790 1/20 0.41
MAP3K14 Q99558 1/20 0.41
DYRK1A Q13627 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10050308 0.84 TSHR (0.55) TSHRNPSR1ACHECA12CA9
SCHEMBL4552573 0.83 TSHR (0.54) TSHRNPSR1ACHECA12CA9
SCHEMBL5037320 0.83 TSHR (0.57) TSHRNPSR1ACHECA12CA9
SCHEMBL3921668 0.83 TSHR (0.57) TSHRCREBBPNPSR1ACHECA12
SCHEMBL3926780 0.83 TSHR (0.57) TSHRNPSR1ACHECA12CA9
SCHEMBL3926777 0.83 TSHR (0.57) TSHRNPSR1ACHECA12CA9
SCHEMBL7099999 0.83 TSHR (0.57) TSHRNPSR1ACHECA12CA9
SCHEMBL3921663 0.83 TSHR (0.57) TSHRCREBBPNPSR1ACHECA12
SCHEMBL15184731 0.79 TSHR (0.53) TSHRACHECA12CA9PARP1
SCHEMBL21591323 0.79 TSHR (0.53) TSHRNPSR1ACHECA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220144847-A1 HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF ELLIPSES PHARMA LTD (GB) 2022-05-12 US disclosed
US-8188080-B2 VHR protein tyrosine phosphatase inhibitors, compositions and methods of use SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2012-05-29 US disclosed
US-20090105254-A1 VHR PROTEIN TYROSINE PHOSPHATASE INHIBITORS, COMPOSITIONS AND METHODS OF USE BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105254-A1 VHR PROTEIN TYROSINE PHOSPHATASE INHIBITORS, COMPOSITIONS AND METHODS OF USE PTPRR, PTPRS, PTPRCAP TSHR 691/4885BRD4 1409/4885CREBBP 3101/4885
US-20220144847-A1 HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF NOTUM, FURIN, CYP4A11 TSHR 3415/4885BRD4 4371/4885CREBBP 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.